全文获取类型
收费全文 | 3860篇 |
免费 | 354篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 178篇 |
妇产科学 | 65篇 |
基础医学 | 468篇 |
口腔科学 | 75篇 |
临床医学 | 452篇 |
内科学 | 853篇 |
皮肤病学 | 48篇 |
神经病学 | 231篇 |
特种医学 | 315篇 |
外国民族医学 | 11篇 |
外科学 | 594篇 |
综合类 | 76篇 |
一般理论 | 1篇 |
预防医学 | 323篇 |
眼科学 | 51篇 |
药学 | 202篇 |
中国医学 | 8篇 |
肿瘤学 | 226篇 |
出版年
2022年 | 23篇 |
2021年 | 82篇 |
2020年 | 31篇 |
2019年 | 56篇 |
2018年 | 109篇 |
2017年 | 104篇 |
2016年 | 96篇 |
2015年 | 84篇 |
2014年 | 134篇 |
2013年 | 172篇 |
2012年 | 181篇 |
2011年 | 178篇 |
2010年 | 136篇 |
2009年 | 144篇 |
2008年 | 156篇 |
2007年 | 165篇 |
2006年 | 160篇 |
2005年 | 141篇 |
2004年 | 123篇 |
2003年 | 112篇 |
2002年 | 127篇 |
2001年 | 126篇 |
2000年 | 100篇 |
1999年 | 92篇 |
1998年 | 97篇 |
1997年 | 76篇 |
1996年 | 88篇 |
1995年 | 77篇 |
1994年 | 52篇 |
1993年 | 58篇 |
1992年 | 81篇 |
1991年 | 89篇 |
1990年 | 75篇 |
1989年 | 76篇 |
1988年 | 76篇 |
1987年 | 54篇 |
1986年 | 50篇 |
1985年 | 43篇 |
1984年 | 42篇 |
1983年 | 39篇 |
1982年 | 19篇 |
1981年 | 33篇 |
1980年 | 18篇 |
1979年 | 21篇 |
1978年 | 25篇 |
1977年 | 34篇 |
1976年 | 26篇 |
1975年 | 15篇 |
1973年 | 13篇 |
1972年 | 12篇 |
排序方式: 共有4229条查询结果,搜索用时 31 毫秒
1.
2.
Reference data for obesity 总被引:1,自引:0,他引:1
3.
HPLC analysis of the embryo-toxic fraction of human uterinefluid, collected between the 22nd and 25th days of the menstrualcycle, revealed the presence of cholic acid at high concentrations.It is suggested that cholic acid could be responsible for theembryo-toxicity of the uterine environment, which follows thereceptive period for implantation. 相似文献
4.
5.
F Roche S Celle V Pichot J-C Barthélémy E Sforza 《The European respiratory journal》2007,29(6):1206-1211
The prevalence of obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is underestimated and its diagnosis is costly and restricted to specialised sleep laboratories. The frequency component of interbeat interval increment (III) has been proposed as a simple and inexpensive diagnostic tool in OSAHS. In a set of 150 patients with clinically suspected sleep-related breathing disorder, the actual predictive accuracy of the power spectral density of the III of the very low frequencies (%VLFI) was analysed by comparing with the apnoea/hypopnoea index (AHI), as assessed by synchronised polysomnography. OSAHS was defined in 100 patients according to an AHI>or=15 events.h(-1). Receiver operator characteristic curves built for %VLFI confirmed that this variable was able to separate OSAHS positive from OSAHS negative with statistical significance. Using an appropriate threshold (>4%), %VLFI demonstrated a positive predictive value of 80%. Misclassification of false-positive subjects occurred when the patient presented significant sleep discontinuity and sleep fragmentation (sleep fragmentation index>or=50 events.h(-1)) related to insomnia or periodic limb movements. A power spectral density of the interbeat interval increment of very low frequencies>4% allowed correct classification of obstructive sleep apnoea/hypopnoea syndrome when the clinical history suggested sleep-related breathing disorders and when moderate-to-severe cases are considered. Higher power spectral density of the interbeat interval increment of very low frequencies may also indicate disrupted sleep in the absence of clear clinical symptoms of sleep apnoea/hypopnoea syndrome. 相似文献
6.
7.
Raymond Tubbs James Pettay Richard Powell David G Hicks Patrick Roche William Powell Thomas Grogan James F Hainfeld 《Applied immunohistochemistry & molecular morphology》2005,13(4):371-375
Ultrasensitive bright field in situ hybridization assays using enzyme metallography (EnzMet) have been developed and validated, but little is known regarding the applicability of EnzMet for immunophenotypic detection of protein via IHC. Superior resolution via discrete metallographic deposits offers the potential for enhancing high-resolution immunophenotyping. Using high-complexity tissue microarrays (TMAs), 88 common solid tumors were evaluated by automated EnzMet (Nanoprobes and Ventana). Targets were chosen to assess the ability of EnzMet to specifically localize encoded antigens in the nucleus (estrogen receptor), cytoplasm (cytokeratins), and cytoplasmic membrane (HER2) in TMAs. Results were compared with conventional IHC diaminobenzidine (DAB) immunostaining. There was full concordance between the EnzMet and conventional IHC results. Furthermore, the EnzMet reaction products did not appreciably diffuse, were dense and sharply defined, and provided excellent high-resolution differentiation of cellular compartments in paraffin sections for the nuclear, cytoplasmic, and cell membrane-localized antigens evaluated. The higher density of elemental silver deposited during enzyme metallography permitted evaluation of core immunophenotypes at a relatively low magnification, allowing more tissue to be screened in an efficient manner. This preliminary study shows the utility of using enzyme metallography for high-resolution immunophenotyping in TMAs. 相似文献
8.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
9.
Abstract End-stage liver disease caused by the hepatitis C virus is a major indication for liver transplantation. However, recurrence of hepatitis in the graft is a major issue. HCV re-infection after transplantation is almost constant, and recent data confirm that it significantly impairs patient and graft survival. Factors that may influence disease severity and consequent progression of HCV graft injury remain unclear. Chronic HCV infection develops in 60%–80% of patients, and 6%–28% ultimately progress to cirrhosis within 5 years. Pre-transplantation antiviral treatment is not easily related to poor tolerance. Attempts to administer prophylactic post-transplantation antiviral treatment are under evaluation but are limited by antiviral drug side effects. Treatment of established graft lesions with interferon or ribavirin as single agents has been disappointing. Combination therapy gave promising results, with sustained virological response in 25% of patients, but indications, modality and duration of treatment should be assessed. 相似文献
10.
In a prospective, randomized, double-blind study, 49 patients underwent lumbar myelography using iotrol (24 patients) or metrizamide (25 patients). The diagnostic imaging adequacy of iotrol was comparable with that of metrizamide. After iotrol myelography, adverse reactions were fewer, less severe, and of shorter duration than were those following metrizamide myelography. Thirteen of 24 patients (54%) receiving iotrol reported some adverse reactions compared with 24 of 25 patients (96%) receiving metrizamide. Five moderate and one severe adverse reaction occurred in the group receiving iotrol. Fourteen moderate and eight severe adverse reactions occurred in the group receiving metrizamide. Thirty-eight patients underwent electroencephalography both before and after myelography (19 iotrol and 19 metrizamide). None of the EEGs obtained after iotrol myelography changed from baseline, while seven of the EEGs obtained after metrizamide myelography showed changes from baseline. Iotrol was judged superior to metrizamide as a contrast medium in this patient population. 相似文献